- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| 27.05. | Belite Bio auf dem Stifel Forum: Strategische Arzneimittelentwicklungen | 1 | Investing.com Deutsch | ||
| 22.05. | Belite Bio-Aktie hält 80 US-Dollar-Kursziel nach FDA-Durchbruchsstatus | 1 | Investing.com Deutsch | ||
| 22.05. | Belite Bio stock holds $80 target on FDA breakthrough nod | 3 | Investing.com | ||
| 21.05. | Belite Bio gets FDA breakthrough therapy status for Stargardt disease treatment | 1 | Seeking Alpha | ||
| 21.05. | BELITE BIO, INC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.05. | Belite Bio Reports Breakthrough Therapy Designation For Tinlarebant | 1 | RTTNews | ||
| 21.05. | Belite Bio, Inc: Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease | 166 | GlobeNewswire (Europe) | Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant's efficacy and favorable safety profileTrial completion expected by Q4 2025 (including a... ► Artikel lesen | |
| 15.05. | Benchmark maintains Buy on Belite Bio stock, $80 price target unchanged | 1 | Investing.com | ||
| 15.05. | Belite Bio stock retains Overweight rating at Cantor Fitzgerald | 1 | Investing.com | ||
| 15.05. | Belite Bio signals positive DSMB review and targets 500-patient PHOENIX trial enrollment completion in Q3 2025 while maintaining strong cash runway | 5 | Seeking Alpha | ||
| 14.05. | Belite Bio GAAP EPS of -$0.27 beats by $0.08 | 1 | Seeking Alpha | ||
| 14.05. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.05. | Belite Bio, Inc: Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update | 84 | GlobeNewswire (Europe) | Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of Tinlarebant in adolescent Stargardt disease (STGD1)... ► Artikel lesen | |
| 29.04. | Belite Bio, Inc: Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 15.04. | BELITE BIO, INC - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 26.03. | Belite Bio stock target raised to $80 at Benchmark | 1 | Investing.com | ||
| 21.03. | BELITE BIO, INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 18.03. | Belite Bio Analysts See Potential For Stock Gains With Progress In Key Trials | 2 | Benzinga.com | ||
| 18.03. | Belite Bio stock holds $100 target post-results | 1 | Investing.com | ||
| 17.03. | Belite Bio GAAP EPS of -$0.32 misses by $0.01 | 1 | Seeking Alpha |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,465 | +0,48 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants... ► Artikel lesen | |
| ARGENX | 515,40 | +0,19 % | argenx SE (ARGX): A Bull Case Theory | ||
| AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,360 | -2,16 % | Protalix BioTherapeutics Inc. Q1 Loss Narrows | JERUSALEM (dpa-AFX) - Protalix BioTherapeutics Inc. (PLX) released Loss for first quarter of -$3.62 millionThe company's earnings came in at -$3.62 million, or -$0.05 per share. This compares... ► Artikel lesen | |
| ENZO BIOCHEM | 0,476 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 30.04.2025 | The following instruments on XETRA do have their last trading day on 30.04.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 30.04.2025ISIN NameCH0347556901 PFBK SCHW.HYP. 17-25... ► Artikel lesen | |
| QUANTERIX | 5,380 | +4,06 % | Quanterix and Akoya Biosciences Announce Amended Merger Agreement | Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination
BILLERICA, Mass. & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 3,900 | +19,27 % | Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights | Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
| TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
| BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen |
Das Unternehmen BELITE BIO INC ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,59 % bei einem Aktienkurs von 52,00 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.